India has been chosen to be one of the three ‘Pilot Countries' along with Egypt and Uganda to launch the WHO's Injection Safety Initiative
SAFE POINT INDIA, India's leading voluntary organization working towards enhanced patient and health worker's safety and to bring down overall healthcare cost through safe injection practices, has urged Prime Minister Narendra Modi to launch a nationwide "Rashtriya Swachh Injections Abhiyan" to end the continued practice of unsafe injections which result in avoidable loss of life, serious health risks and increased healthcare burden.
"We wish to draw the attention of Prime Minister Shri Narendra Modi Ji towards the menace of unsafe injection practices and sincerely urge him to use his good office to launch ‘Rashtriya Swachh Injections Abhiyan', said Mr Rajiv Nath, Project Director & Trustee, and Safe Point India.
Explaining the urgent need for such a nationwide programme, Mr Nath pointed out that "Injections should be life giver, not life taker but unsafe injection practices, mostly in the form of reuse of safety injections from dirty contaminated needles, continues to be a serious threat to life of patients and health workers, casting shadows over public healthcare and immunization programme while raising individual and national healthcare cost burden."
Mr Nath added that such a campaign would be relatively lower cost but concomitant benefits in terms of health, safety and hidden savings in saving lives or loss from income due to extra days on a hospital bed or taxpayers money in treatment costs, would be humungous.
Studies and common medical observations have found that unsafe injections can result in the transmission of blood-borne pathogens from patient to patient (through reuse of syringes); patient to healthcare worker (through needle-stick injuries) and at times from health worker to patient. The community at large is also at risk when used injection equipment is not safely disposed of. Unsafe injection practices have also been the cause of outbreaks of viral hepatitis B and C and HIV in healthcare settings including in high income countries.